Robert A. Stewart has joined Watson Pharmaceuticals in the newly created position of senior vice president, Global Operations, effective immediately. Mr. Stewart will be responsible for global manufacturing, supply chain, quality and technical operations. He joins the company from Abbott Laboratories, where he most recently served as divisional vice president, Global Supply Chain.

Also, Thomas R. Russillo has been named executive vice president, Global Generics and will head the company’s newly formed Global Generics commercial function. Mr. Russillo will have overall responsibility for generic sales and marketing for the U.S. and Canada, as well for all international markets once the acquisition of Arrow Group is complete. Previously, he served as executive vice president and president of Watson’s Generics Division since 2006. Both Mr. Stewart and Mr. Russillo report to Paul Bisaro, president and chief executive officer of Watson.

“As we prepare to maximize our global footprint following the acquisition of the Arrow Group, we are refining our management structure in ways that will enhance our ability to aggressively capitalize on expanded opportunities,” said Mr. Bisaro. “Bob brings more than 20 years of experience in global pharmaceutical supply chain management. By centralizing all quality and supply chain functions under his leadership, we can ensure that we more effectively continue to pursue additional cost and operational efficiencies under our Global Supply Chain Initiative and Operational Excellence programs. In addition, Bob’s extensive international experience will help us maximize the increased international capabilities we gain following the closing of the Arrow acquisition.”

Mr. Bisaro continued, “By creating this Global Generics commercial structure, we will look to Tom to develop the strategies that will strengthen and grow Watson’s and Arrow’s current product portfolios and market positions around the world. He will also have responsibility for ensuring that our commercial needs are appropriately aligned with new product R&D and that Watson efficiently expands its generics position with key product introductions across the 20 countries in which we will operate, including established, expanding and emerging markets.”